WO2002041828A2 - Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon - Google Patents
Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon Download PDFInfo
- Publication number
- WO2002041828A2 WO2002041828A2 PCT/US2001/043123 US0143123W WO0241828A2 WO 2002041828 A2 WO2002041828 A2 WO 2002041828A2 US 0143123 W US0143123 W US 0143123W WO 0241828 A2 WO0241828 A2 WO 0241828A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erbb
- cancer
- compound
- cells
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Definitions
- the present invention relates to methods and compositions for inhibiting the activity of erbB-2.
- the described methods and compositions are particularly useful for inhibiting cellular proliferative disorders, such as cancer, characterized by over-activity and/or inappropriate activity of erbB-2.
- receptors which are dispersed on the outer surface of the cell and function as "molecular antennae.” These receptors detect an incoming messenger and activate a signal pathway that ultimately regulates a cellular process such as secretion, contraction, metabolism or growth.
- transduction mechanisms translate external signals into internal signals, which are then carried throughout the interior of the cell by chemicals known as "second messengers.”
- second messengers In molecular terms, the process depends on a series of proteins within the cellular plasma membrane, each of which transmits information by inducing a conformational change in the protein next in line. At some point, the information is assigned to small molecules or even to ions within the cell's cytoplasm, which serve as the above-mentioned second messengers. The diffusion of the second messengers enables a signal to propagate rapidly throughout the cell.
- Cancer is the leading cause of death, second only to heart disease in both men and women.
- Breast cancer is the most common tumor in women, representing 32% of all new cancer cases and causing 18% of cancer-related deaths of women in the United States.
- numerous techniques have been developed and are the subject of current research to understand the nature and cause of the disease, and to provide techniques for the control or cure thereof.
- One promising avenue for the development of cancer treatments is based on blocking abnormal cell signaling pathways. Particular efforts are directed to the elucidation and regulation of the activity of receptor and transmembrane proteins.
- the human epidermal growth factor is a six kilodalton (kDa), 53 amino acid, single-chain polypeptide which exerts its biological effect by binding to a specific 170 kDa cell membrane receptor (EGF-R).
- the human EGF-R consists of an extracellular domain with a high cysteine content and N-linked glycosylation, a single transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity.
- EGF-R EGF-R receptor- mediator pathways that lead to pleiotropic biological effects including excessive proliferation and metastasis.
- Examples include prostate cancer, breast cancer, lung cancer, head and neck cancer, bladder cancer, melanoma, and brain tumors.
- EGF-R epidermal growth factor receptor
- EGF-R and its physiologic ligands play a prominent role in the growth regulation of many normal and malignant cell types.
- EGF epidermal growth factor
- TGF alpha transforming growth factor alpha
- EGF receptor system One role the EGF receptor system may play in the oncogenic growth of cells is through autocrine- stimulated growth. Cells that express EGF-R and secrete EGF and/or TGF alpha can stimulate their own growth, thereby creating a cancerous condition.
- An autocrine growth stimulatory pathway analogous with that proposed for epidermal growth factor receptor and its ligands may also be employed by a growing list of oncogene encoded transmembrane proteins that have a structure reminiscent of that of the growth factor receptors.
- One such example is the HER-2/neu or c-erbB-2 oncogene, which belongs to the erbB-like oncogene group, and is related to, but distinct from EGF-R.
- the erbB-2 gene encodes a 185 kD transmembrane glycoprotein that has partial homology with other members of the EGFR family.
- the expressed protein has been suggested to be a growth factor receptor due to its structural homology with EGFR.
- known EGFR ligands, such as EGF or TGF ⁇ do not bind to p 185 -erbB-2.
- the erbB-2 oncogene has been demonstrated to be implicated in a number of human adenocarcinomas leading to elevated levels of expression of the p protein product.
- the erbB-2 oncogene has been found to be amplified in breast, ovarian, gastric and even lung adenocarcinomas.
- the amplification of the c-erbB-2 oncogene has been found in many cases to be a significant, if not the most significant, predictor of both overall survival time and time to relapse in patients suffering from such forms of cancer.
- Carcinoma of the breast and ovary account for approximately one-third of all cancers occurring in women and together are responsible for approximately one-fourth of cancer-related deaths in females.
- the c-erbB-2 oncogene has been found to be amplified in 25 to 30% of human primary breast cancers and it has been associated with a high risk of relapse and death.
- overexpression abnormal cell proliferation is believed to be caused by extremely high tyrosine kinase activity and the resulting high level of signal transduction.
- Overexpression of erbB-2 has also been found to be associated with increased resistance to chemotherapy or patients with elevated levels of erbB-2 respond poorly to many drugs. It is believed that decreasing the levels of erbB-2 will allow chemotherapeutic drugs to be more effective. Therefore, therapies targeted at erbB-2 have the great therapeutic potential for the treatment of breast cancers.
- erbB-2 is a clinically proven therapeutic target for breast cancer.
- Herceptin is recognized as the first in what promises to-be a wave of therapies attacking cancer at its genetic roots.
- erbB-2 kinase inhibitor compounds that are capable of entering the cell, blocking tyrosine kinase activity and shutting down the signal transduction pathway mediated by erbB-2 may be used as potential therapeutic agents for the treatment of breast cancer.
- tyrosine kinase inhibitors synergize with antibodies to EGF-R to inhibit the growth of aquamous cell carcinoma in vivo.
- a specific erbB-2 kinase inhibitor may also have synergistic effects with Herceptin in the treatment of breast cancer.
- such therapies will comprise treatment of cancer and other neoplastic conditions.
- Figure 1 shows the structure of houttuyninum.
- Figure 2 shows the inhibition of erbB-2 phosphorylation in BT-474 and MDA-453 cells by houttuyninum compound.
- Figure 3 shows the inhibition of MAPK activation in BT-474 and MDA-453 cells by houttuyninum compound.
- Figure 4 shows the inhibition of AKT activation in BT-474 and MDA-453 cells by houttuyninum compound.
- Figure 5 shows the inhibition of HER2 phosphorylation in MDA-453 cells by houttuyninum compound.
- Figure 6 shows the inhibition of EGFR phosphoiylation in A431 and MDA-468 cells by houttuyninum compound.
- Figure 7 shows the inhibition of HER2 activation
- MDA-453 cells by houttuyninum compound by houttuyninum compound.
- MDA-453 cells by houttuyninum compound by houttuyninum compound.
- MDA-453 cells by houtttuyninum compound by houtttuyninum compound.
- Figure 10 shows the inhibition of HER2 activation in BT-474 cells by houttuyninum compound.
- Figure 11 shows the inhibition of MAPK activation BT-474 cells by houttuyninum compound.
- Figure 13 shows the inhibition of erbB-2 phosphorylation in AKT activation BT-474 cells by the soluble extract of houtttuynum.
- Figure 14 Effects of the soluble extract houttuynum (YXl, 2mg/ml in original stock) on phosphorylation of erbB-2 in MDA-453 or EGFR in MDA-468 cells.
- Figure 15 Effects of the soluble extract houttuynum (YXl 2 mg/ml in original stock) on protein expression of erbB-2 in MDA-453 or EGF-R in MDA-468 cells.
- Figure 16. Enhanced cytotoxicity of Doxrubicin in erbB-2 overexpressing human breast cancer cells BT-474 cells by the soluble extract houttuynum (YXl 2 mg/ml in original stock).
- Figure 17 Enhanced cytotoxicity of Cisplatin in erbB-2 overexpressing human breast cancer cells BT-474 cells by the soluble extract houttuynum (YXl 2 mg/ml in original stock).
- Figure 18 Enhanced cytotoxicity of VP-16 in erbB-2 overexpressing human breast cancer cells BT-474 cells by the soluble extract houttuynum (YXl 2 mg/ml in original stock).
- Figure 19 Effect of the soluble extract houttuynum (YXl, 2 mg/ml in original stock) or houttuyninum compound (YX2) on in vivo tumor proliferation of erbB-2 overexpressing human cancer cell line N87.
- erbB-2 which encodes tyrosine kinase receptor pl85neu
- the overexpression of erbB-2 plays a key role in tumor generation or progression such as breast cancer, ovarian cancer, etc.
- houttuynum, Houttuymia cordata, and neo-houttuyninum (decanoyl acetaldehyde) selectively suppressed autophosphorylation of erbB-2 tyrosine kinase in breast cancer cell lines MDA-453 and BT-474, and thus inhibited the activity of erbB-2.
- a first aspect of the invention provides therapies using compounds capable of inhibiting erbB-2 kinase activity.
- Such compounds according to the invention include soluble extract of houttuynum, or compound houttuyninum, Houttuymia cordata, neo-houttuyninum (decanoyl acetaldehyde), analogs thereof, pharmaceutically acceptable salts thereof, and/or prodrugs thereof.
- Houttuynum is an antibacterial agent from Chinese herbal medicine that has been shown to have non- or low toxicity to humans.
- Houttuynia cordata is an antimicrobial agent from Chinese herbal medicine that has been used to treat various infections such as bronchitis, pneumonia, whooping cough, and urinary infections.
- a therapy according to the invention can involve a method for the treatment of a cellular proliferative disorder characterized by over-activity or inappropriate activity of erbB-2 comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of houttuyninum, Houttuymia cordata, neo-houttuyninum (decanoyl acetaldehyde), analogs thereof, pharmaceutically acceptable salts thereof, and/or prodrugs thereof.
- cellular proliferative disorders refer to disorders wherein unwanted cellular proliferation of one or more subset(s) of cells in a multicellular organism occurs, resulting in harm (e,g., discomfort or decreased life expectancy) to the multicellular organism and can include, for example, cancers, blood vessel proliferative disorders, and fibrotic disorders.
- a particular disorder is considered to be "driven” or caused by a particular receptor tyrosine kinase if the disorder is characterized by over-activity, or inappropriate activity, of the kinase.
- misappropriate activity refers to either: 1) erbB-2 expression in cells which normally do not express such receptors; 2) increased erbB-2 expression leading to unwanted cell proliferation such as cancer; 3) increased erbB-2 activity leading to unwanted cell proliferation, such as cancer; and/or over-activity of erbB-2.
- over-activity refers to either an amplification of the gene encoding the specific receptors or the production of a level of erbB-2 activity which can be correlated with a cell proliferative disorder (i.e., as the level of erbB-2 increases, the severity of one or more of the symptoms of the cell proliferative disorder increases).
- Another aspect of the invention provides a class of erbB- 2 inhibitor compositions comprising, in admixture with a pharmaceutically acceptable carrier, a therapeutically effective amount of a compound that is capable of inhibiting erbB-2 activity.
- a compound that is capable of inhibiting erbB-2 activity include soluble extract of houttuynum, houttuyninum, Houttuynia cordata, neo-houttuyninum (decanoyl acetaldehyde), analogs thereof, pharmaceutically acceptable salts thereof, and/or prodrugs thereof.
- the term "therapeutically effective” generally refers to either the inhibition, to some extent, of growth of cells causing or contributing to a cell proliferative disorder; or the inhibition, to some extent, of the activity of erbB-2.
- houttuynum was unexpectedly found to inhibit erbB-2 phosphorylation.
- ErbB-2 autophosphorylation was shown to be inhibited by houttuynum in different breast cancer cell lines, such as MDA-453 (MDA-453), and BT-474 (BT-474).
- MDA-453 MDA-453
- BT-474 BT-474
- concentrations of at least 2.5 ⁇ g/ml houttuynum obviously inhibited erbB-2 kinase.
- MDA-453 cells which overexpress erbB-2
- MDA-468 cells which overexpress EGF-R
- houttuynum inhibits growth of MDA-453 cells more than that of MDA-468.
- the compounds according to the invention can be used to treat cellular proliferative disorders wherein inhibition of erbB-2 kinase signaling is therapeutically beneficial.
- This will include disorders that involve abnormal cell growth and/or differentiation, such as cancers and other neoplastic conditions.
- the subject compounds may be used to treat other conditions involving abnormal cell proliferation and/or differentiation, such as dermatological conditions and disorders.
- the subject compounds may be useful in treating inflammatory conditions such as arthritis, psoriasis, autoimmune disorders such as myasthenia gravis, lupus, multiple sclerosis, and others, and conditions involving abnormal platelet aggregation.
- the preferred indication is cancer, especially cancers involving over-expression of erbB-2, EGF, and/or the PDGF receptor, cancers that express mutant ras, or cancers that comprise a Bcr/Abl translocation.
- cancers that may be treated according to the invention include breast, colon, pancreatic, prostate, head and neck, gastric, renal, ovary, brain and lung cancers.
- the subject therapies can comprise the administration of soluble extract, and/or at least one compound according to the invention in a therapeutically effective amount, e.g., an amount sufficient to inhibit tumor cell proliferation and/or differentiation and/or promotion of apoptosis.
- the soluble extract or compound may be administered by any pharmaceutically acceptable means, by either systemic or local administration. Suitable modes of administration include oral, dermal , e.g., via transdermal patch, inhalation, via infusion, intranasal, rectal, vaginal, topical parenteral (e.g., via intraperitoneal, intravenous, intramuscular, subcutaneous, injection).
- oral administration or administration via injection is preferred.
- the subject compounds may be administered in a single dosage or chronically dependent upon the particular disease, condition of patient, toxicity of compound, and whether this compound is being utilized alone or in combination with other therapies. Chronic or repeated administration will likely be preferred based on other chemotherapies.
- the subject compounds can be administered as erbB-2 inhibitor compositions comprising, in admixture with a pharmaceutically acceptable carrier, a therapeutically effective amount of a compound of the invention.
- a pharmaceutically acceptable carrier examples include injectable solutions, tablets, milk, or suspensions, creams, oil-in-water and water-in- oil emulsions, microcapsules and micro vesicles.
- These compositions can comprise conventional pharmaceutical excipients and carriers typically used in drug formulations, e.g., water, saline solutions, such as phosphate buffered saline, buffers, and surfactants.
- the subject compounds may be free or entrapped in microcapsules, in colloidal drug delivery systems such as liposomes, microemulsions, and macroemulsions. Suitable materials and methods for preparing pharmaceutical compositions are disclosed in Remington's Pharmaceutical Chemistry, 16 Edition, (1980). Also, solid compositions containing the subject compounds, such as tablets, and capsule formulations, may be prepared. Suitable examples thereof include semipermeable materials of solid hydrophobic polymers containing the subject compound which may be in the form of shaped articles, e.g., films or microcapsules, as well as various other polymers and copolymers known in the art.
- the compounds described herein can be used alone, in combination with other pharmaceutically active agents able to inhibit protein kinase activity (e.g., anti-sense nucleic acid and ribozymes targeted to nucleic acid encoding a receptor tyrosine kinase, and antibodies able to modulate tyrosine kinase activity, such as anti-erbB-2 antibodies which may work by modulating erbB-2, and in combination with other types of treatment for cell proliferative disorders, such as chemotherapy.
- other pharmaceutically active agents able to inhibit protein kinase activity e.g., anti-sense nucleic acid and ribozymes targeted to nucleic acid encoding a receptor tyrosine kinase, and antibodies able to modulate tyrosine kinase activity, such as anti-erbB-2 antibodies which may work by modulating erbB-2, and in combination with other types of treatment for cell proliferative disorders, such as chemotherapy.
- chemotherapeutic agents are known in art for treating breast cancer, including doxorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, mitomycin C, mitoxantrone, taxol, and epirubicin.
- chemotherapeutic agents are also known in the art for treating different types of leukemia, including the treatment of AML using daunorubicin, cytarabine (Ara-C), doxorubicin, amsacrine, mitoxantrone, etoposide (VP-16), thioguanine, mercaptopurine, and azacytidine; the treatment of ALL using vincristine, prednisone, doxorubicin and asparginase; the treatment of CML using busulfan and hydroxyurea; and the treatment of CLL using chlorambucil and cyclophosphamide. Additional treatments include use of alpha-interferon, bone marrow transplantation and transplantation of peripheral blood or umbilical cord blood stem cells.
- the dosage effective amount of compounds according to the invention will vary depending upon factors including the particular compound, toxicity, and inhibitory activity, the condition treated, and whether the compound is administered alone or with other therapies.
- a dosage effective amount can be at least about 0.25 ⁇ g/ml, preferably from about 2.5 ⁇ g/ml to about 400 ⁇ g/ml, and more preferably about 5 ⁇ g/ml to about 50 ⁇ g/ml.
- the compounds of the invention can preferentially and selectively inhibit erbB-2 activity.
- the subjects treated will typically comprise mammals, and most preferably will be human subjects, e.g., human cancer subjects.
- the human breast cancer cell lines MDA-453 also known as MDA-MB-453ml
- BT-474 also known as BT- 474ml
- MDA-468 and A431 were obtained from American Type culture collection (Rockville, MD).
- BT-474 was grown in DMEM medium (Life Technologies, Inc. Grand Island, NY) supplemented with 10% fetal bovine serum).
- MDA-453, MDA- 468 and A431 were cultivated in RMPI-1640 medium (Life Technologies, Inc.). Cells were grown in an incubator at 37 °C under 5% C02 in air.
- ErbB-2 antibody was obtained from Calbiochem Co.
- Anti-tyrosine antibody (PY99) was purchased from Santa Cruz.
- Anti-Akt, phospho-Akt, MAPK and phospho- MAPK antibody was purchased from BioLab co. Houttuynum was synthesized in house.
- Cells were seeded at a density of 2 x 10 5 cells/well in 12- well plate. The next day, the regulatory medium was aspirated and replaced with serum-free medium. Drug stock was added to indicated concentrations. After treatment with houttuynum for 1 hour, cells were washed twice with PBS, and lysed in 100 ul of lysis buffer (20 mM Na2PO4(pH 7.4), 150mM NaCl, 1% Triton X-100, 1% aprotinin, ImM phenymethysulfonyl fluoride, 10 mg/mL leupeptin, 100 mM NaF, and 2 mM Na3VO4).
- lysis buffer (20 mM Na2PO4(pH 7.4), 150mM NaCl, 1% Triton X-100, 1% aprotinin, ImM phenymethysulfonyl fluoride, 10 mg/mL leupeptin, 100 mM NaF, and
- Lysates were centrifuged at 12000 rpm for 10 min. The supernatant was collected. The protein content was determined using the Bio- Rad protein assay (Bio-Rad laboratories, Hercules CA). A total of 40 ⁇ g of protein was resolved by SDS-PAGE using 4-20% gel and transferred electrophoretically to nitrocellulose membrane (Amersham Co.). The membranes were blotted for 30 min at 25 °C with nonfat dry milk (5%) in TBST (20mM Tris-HCl, pH7.4, 150 mM NaCl, 0.1% Tween), and then incubated with primary antibodies for 2 hours at 25 °C.
- TBST 20mM Tris-HCl, pH7.4, 150 mM NaCl, 0.1% Tween
- the membranes were washed with TBST and incubated horseradish perioxidase-labeled anti- mouse or rabbit secondary antibody for 1 hour at 25 °C. Being washed with TBST, the bound antibody complex was detected using an ECL chemiluminescence reagent and XAR film (Kodak) as described by the manufacturer (Amersham).
- MDA-453 cells were plated at a density of 5 x 10 5 cells per well in 12-well plate. The next day, then regular medium was changed into serum-free medium. Drug stock was added. Following treatment with lOug/ml of houttuynum for 30 min, cells were washed twice with serum-free medium. 1 ml of serum-free medium was added and incubated in an incubator at 37 °C under 5% C02 in air for different periods of time. Cells were lysed and western blot assay was conducted.
- MDA-453, BT-474, SKBr3, MDA-361 human breast cancer cells that overexpress pl85 neu were used to test the effect of houttuynum on tyrosine phosphorylation of erbB-2.
- MDA-453, BT-474, SKBr3, MDA-361 human breast cancer cells that overexpress pl85 neu were used to test the effect of houttuynum on tyrosine phosphorylation of erbB-2.
- the degree of erbB-2 autophosphorylation was conducted.
- Houttuynum inliibited tyrosine phosphorylation of pl85 neu significantly under the concentrations of 5,10 ⁇ g/ml in MDA- 453 and BT-474 (Figs. 1, 6, and 9).
- the same filter was stripped, and was blocked with 5% fat-free milk.
- anti-erbB-2 antibody as the primary antibody, erbB-2 protein level was detected using Western blot analysis. The results showed that erbB-2 protein expression had no change following houttuynum treatment.
- houttuynum can inhibit erbB-2 kinase.
- EGF-R tyrosine kinase activity was tested.
- the inhibitory effect on EGF-R tyrosine kinase activity was found to be weak under 20 ug/ml of concentration of houttuynum.
- concentration escalated to 100 ug/ml houttuynum had a significant inhibitory effect on EGF-R tyrosine kinase.
- a diagnostic assay to determine whether a particular disorder is driven by erbB-2 can be carried out using the following steps: 1) culturing test cells or tissues; 2) administering a compound according to the invention which can selectively inhibit erbB-2 activity; and 3) measuring the degree of growth inhibition of the test cells. These steps can be carried out using standard techniques in light of the present disclosure. For example, standard techniques can be used to isolate cells or tissues and culturing in vitro or in vivo.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002239258A AU2002239258A1 (en) | 2000-11-17 | 2001-11-19 | Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24927200P | 2000-11-17 | 2000-11-17 | |
US60/249,272 | 2000-11-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002041828A2 true WO2002041828A2 (en) | 2002-05-30 |
WO2002041828A3 WO2002041828A3 (en) | 2002-08-01 |
Family
ID=22942748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/043123 WO2002041828A2 (en) | 2000-11-17 | 2001-11-19 | Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002239258A1 (en) |
WO (1) | WO2002041828A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004040010A1 (en) * | 2002-10-31 | 2004-05-13 | Astrazeneca Ab | Assay for the screening of compounds acting through erbb-2 |
US7342046B2 (en) | 2004-03-25 | 2008-03-11 | The Regents Of The University Of Michigan | Gossypol co-crystals and the use thereof |
US7354928B2 (en) | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
US7427689B2 (en) | 2000-07-28 | 2008-09-23 | Georgetown University | ErbB-2 selective small molecule kinase inhibitors |
US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
WO2011091719A1 (en) * | 2010-01-29 | 2011-08-04 | Liu Li | Crystalline hydrates of alkyl acyl acetaldehyde sulfite, preparation methods and uses thereof |
CN103265459A (en) * | 2013-06-03 | 2013-08-28 | 四川省惠达药业有限公司 | Novel sodium houttuyfonate compound as well as preparation method and pharmaceutical composition thereof |
US20140194528A1 (en) * | 2013-01-10 | 2014-07-10 | Hong Kong Baptist University | Usage of sodium houttuyfonate on inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis |
CN107095870A (en) * | 2017-06-13 | 2017-08-29 | 佛山科学技术学院 | A kind of compound medicament composition acted on anti-lymphadenoma and application thereof |
CN112336744A (en) * | 2020-12-08 | 2021-02-09 | 河南省医药科学研究院 | New houttuynin sodium and its application in preparing antineoplastic medicine by combining with cisplatin |
CN112791074A (en) * | 2021-03-17 | 2021-05-14 | 中山大学 | Application of houttuynin and/or sodium new houttuyfonate in preparing NDM-1 inhibitor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59152323A (en) * | 1983-02-08 | 1984-08-31 | Moriyuki Hiramatsu | Fomentation |
JPS61249929A (en) * | 1985-04-25 | 1986-11-07 | Koichi Sakurai | Production of herb drink effective to gastric cancer and gastric ulcer and the like |
CN1086723A (en) * | 1993-06-09 | 1994-05-18 | 吴传福 | The manufacture method of compound pulmonary carcinoma tablet |
CN1048164C (en) * | 1993-08-24 | 2000-01-12 | 吴雪姣 | Oral liquid |
CN1087612C (en) * | 1994-05-21 | 2002-07-17 | 崔延宏 | Anti-cancer compound preparation |
CN1114570A (en) * | 1994-07-02 | 1996-01-10 | 云南滇东北制药总厂 | Qingyan Jiedu Koufuye (oral liquor capable of relieving sore-throat and detoxicating) and preparing method thereof |
CN1067263C (en) * | 1998-03-09 | 2001-06-20 | 张富永 | Xiaoaisan powder for curing cancer |
-
2001
- 2001-11-19 AU AU2002239258A patent/AU2002239258A1/en not_active Abandoned
- 2001-11-19 WO PCT/US2001/043123 patent/WO2002041828A2/en not_active Application Discontinuation
Non-Patent Citations (7)
Title |
---|
DATABASE DWPI [Online] 'Method for producing compound pulmonary carcinoma tablet', XP002951257 Retrieved from WEST & CN 1 086 723 A 18 May 1994 * |
DATABASE DWPI [Online] 'Oral Chinese herbal medicine having anti-cancer properties', XP002951256 Retrieved from WEST & CN 1 113 789 A 27 December 1995 * |
DATABASE DWPI [Online] 'Oral liquid for smokers for e.g. relieving sore-throat', XP002951255 Retrieved from WEST & CN 1 114 570 A 10 January 1996 * |
DATABASE DWPI [Online] 'Oral liquid for treating rheumatoid diseases and cancer', XP002951256 Retrieved from WEST & CN 1 105 246 A 19 July 1995 * |
DATABASE DWPI [Online] 'Xiaoaisan powder for curing cancer', XP002951253 Retrieved from WEST & CN 1 228 310 A 15 September 1999 * |
DATABASE JPAB [Online] 'Fomentation', XP002951254 Retrieved from WEST & JP 59 152 323 A 31 August 1984 * |
DATABASE JPAB [Online] 'Production of herb drink effective to gastric cancer and gastric ulcer and the like', XP002951252 Retrieved from WEST & JP 61 249 929 A 07 November 1986 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427689B2 (en) | 2000-07-28 | 2008-09-23 | Georgetown University | ErbB-2 selective small molecule kinase inhibitors |
US8163805B2 (en) | 2001-05-30 | 2012-04-24 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7354928B2 (en) | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
WO2004040010A1 (en) * | 2002-10-31 | 2004-05-13 | Astrazeneca Ab | Assay for the screening of compounds acting through erbb-2 |
US7342046B2 (en) | 2004-03-25 | 2008-03-11 | The Regents Of The University Of Michigan | Gossypol co-crystals and the use thereof |
US7432300B2 (en) | 2004-03-25 | 2008-10-07 | The Regents Of The University Of Michigan | Gossypol co-crystals and the use thereof |
WO2011091719A1 (en) * | 2010-01-29 | 2011-08-04 | Liu Li | Crystalline hydrates of alkyl acyl acetaldehyde sulfite, preparation methods and uses thereof |
CN102153492A (en) * | 2010-01-29 | 2011-08-17 | 刘力 | Treatment medicament for resisting infectious diseases, and preparation method and application thereof |
CN102153492B (en) * | 2010-01-29 | 2016-01-13 | 刘力 | Medicine of anti-infectious disease and its production and use |
US20140194528A1 (en) * | 2013-01-10 | 2014-07-10 | Hong Kong Baptist University | Usage of sodium houttuyfonate on inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis |
CN103265459B (en) * | 2013-06-03 | 2015-09-09 | 四川省惠达药业有限公司 | A kind of novel sodium houttuyfonate compound, its preparation method and pharmaceutical composition thereof |
CN103265459A (en) * | 2013-06-03 | 2013-08-28 | 四川省惠达药业有限公司 | Novel sodium houttuyfonate compound as well as preparation method and pharmaceutical composition thereof |
CN107095870A (en) * | 2017-06-13 | 2017-08-29 | 佛山科学技术学院 | A kind of compound medicament composition acted on anti-lymphadenoma and application thereof |
CN107095870B (en) * | 2017-06-13 | 2019-05-21 | 佛山科学技术学院 | A kind of compound medicament composition and application thereof with anti-lymphadenoma effect |
CN112336744A (en) * | 2020-12-08 | 2021-02-09 | 河南省医药科学研究院 | New houttuynin sodium and its application in preparing antineoplastic medicine by combining with cisplatin |
CN112336744B (en) * | 2020-12-08 | 2023-03-07 | 河南省医药科学研究院 | New houttuynin sodium and its application in preparing antineoplastic medicine by combining with cisplatin |
CN112791074A (en) * | 2021-03-17 | 2021-05-14 | 中山大学 | Application of houttuynin and/or sodium new houttuyfonate in preparing NDM-1 inhibitor |
Also Published As
Publication number | Publication date |
---|---|
AU2002239258A1 (en) | 2002-06-03 |
WO2002041828A3 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7427689B2 (en) | ErbB-2 selective small molecule kinase inhibitors | |
Pérez-Sayáns et al. | Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases | |
US7446124B2 (en) | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents | |
JP5650639B2 (en) | Treatment of tumor diseases | |
WO2002041828A2 (en) | Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon | |
US20160145302A1 (en) | A short peptide targeting eps8 binding with egfr and use thereof | |
US20150087598A1 (en) | Treating muc1-expressing cancers with helicase inhibitors | |
EP3398949B1 (en) | Uses of compound in preparation of drugs for treating brain glioma | |
US20140056910A1 (en) | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug | |
CN107243079B (en) | A pharmaceutical composition containing rhein and its application in preparing antitumor drugs | |
KR102561285B1 (en) | Novel HER3 inhibitor and pharmaceutical composition for preventing or treating for cancer comprising the same | |
CN116462669B (en) | SOS1 and EGFR double-target compound, and preparation method and application thereof | |
CN116327772A (en) | Targeting treatment method for bone metastasis of SMO inhibitor Sonidegib to tubular breast cancer | |
WO2022211027A1 (en) | Cd9 signal suppressing agent and use thereof | |
CN114288410B (en) | Application of SRC inhibitor and FAK inhibitor in preparation of medicines for inhibiting lung cancer metastasis | |
Xiao et al. | A phenylpentane derivative from Sanghuangporus vaninii inhibits EMT mediated tumor progression of pancreatic cancer by targeting EGFR | |
TWI808063B (en) | Method for treatment or prevention of a cancer | |
EP4349339A1 (en) | Pharmaceutical composition for treatment of cancer and use thereof | |
KR102133205B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising PNA-pHLIP Conjugates | |
CN117379551A (en) | Combined therapy for tumor | |
US20230348564A1 (en) | Anti-cancer proteins | |
WO2024077358A1 (en) | Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones. | |
Kohgo et al. | 2. Role of Apoptosis on Morphogenesis and Therapy in Malignancy | |
CN112121043A (en) | Application of dicoumarol in antitumor | |
KR20230110296A (en) | Kinase Inhibitor Combinations for Cancer Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC(THE EPO COMMUNICATION= EPO FORM 1205A DATED 20.11.2003) |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |